Back

Hypobaric hypoxia drives citrate cycle reprogramming to suppress tumor progression

Gao, Y.; He, X.; E, G.; Wang, Y.; Huang, S.; Cai, D.; Deng, Y.; Gan, P.; Feng, R.; Liang, Q.; Tang, Z.; Xu, G.; Chen, J.; Xue, H.; Wang, Q.; Liu, H.; Li, G.; Zeng, S.; Xie, M.; Gao, Y.; Gong, J.; Zhang, E.

2025-08-20 cancer biology
10.1101/2025.08.15.669572 bioRxiv
Show abstract

High altitude residents present lower tumor incidence and mortality than plain residents, suggesting that hypobaric hypoxia displays protective effect against tumor development. The results of our studies showed that hypobaric hypoxia exposure significantly suppressed tumor progression in subcutaneous bearing and lung metastasis tumor models. With single-cell transcriptome analysis, we identified HIF-1 pathway was significantly downregulated in tumor tissues with high altitude hypoxia, leading to decreased glycolysis and angiogenesis and improved antitumor immune response. Mechanistically, systemic hypoxia rewired citric acid cycle, with enhanced CS and IDH2 expression and reduced OGDH and SUCLG2 expression, to induce -ketoglutarate accumulation and succinate decline in tumor microenvironment, further mediating HIF-1 pathway inhibition. Moreover, hypobaric hypoxia treatment significantly improved the antitumor effects of adjuvant therapies (including chemotherapy, anti-angiogenic therapy and immunotherapy). Our findings reveal the role and mechanism of hypobaric hypoxia for tumor regression and yield new insights into tumor therapy.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.